In a significant advancement in public health research, the Indian Council of Medical Research (ICMR) has introduced the country’s first stigma measurement tool specifically for Sickle Cell Disease (SCD), known as the India Sickle Cell Disease Stigma Scale (ISSSI). This development is crucial as India has one of the highest prevalence rates of SCD globally, trailing only sub-Saharan Africa.
Sickle Cell Disease is a genetic disorder characterized by the production of abnormal haemoglobin, leading to a range of health complications, including severe pain episodes, chronic fatigue, infections, and organ damage. Individuals afflicted with the disease often face significant challenges that can severely affect their quality of life and overall wellbeing.
Stigma associated with SCD has been poorly studied in India, and until the ISSSI’s introduction, there were no appropriate tools to measure this stigma within the culturally diverse Indian context. The newly developed scale was created to reflect the unique socio-cultural aspects of Indian society and provides a structured way to measure various dimensions of stigma, such as:
– Familial and Reproductive Stigma: How familial expectations and perceptions affect patients and their reproductive choices.
– Social Disclosure: The challenges individuals face when revealing their condition to others.
– Illness Burden: The personal and societal burdens placed on individuals due to their illness.
– Interpersonal Relationships: The impact of SCD on relationships with family and friends.
– Healthcare Interaction Problems: The level of stigma encountered within healthcare systems.
A recent study published in The Lancet Regional Health – South-East Asia validated both the patient scale (ISSSI-Pt) and caregiver scale (ISSSI-Cg), demonstrating their effectiveness in measuring the stigma associated with SCD. This rigorous methodological approach assures that the ISSSI scales are reliable tools for clinical and research contexts, enhancing the understanding of stigma in patients and caregivers alike.
The study was conducted across six districts in India known to be endemic for SCD: Alluri Seetharama Raju in Andhra Pradesh, Anuppur in Madhya Pradesh, Chhoteudepur in Gujarat, Kandhamal in Odisha, Mysuru in Karnataka, and Udalguri in Assam. These selected locations represent a diverse array of socio-economic conditions and healthcare accessibility, providing a comprehensive overview of the challenges faced by SCD patients in India.
The introduction of the ISSSI marks an important step in addressing the stigma surrounding SCD, which is especially prevalent in tribal and marginalized communities. This stigma can lead to social isolation, discrimination, and inadequate access to health services, compounding the physical challenges that patients already endure.
In response to this public health crisis, India has also launched a national initiative targeting the elimination of sickle cell anaemia as a public health problem. The comprehensive management plan encompasses a variety of interventions aimed at improving care and awareness, thereby reducing the stigma that hinders treatment and support for those affected by SCD.
-Raja Aditya
